CureVac (NASDAQ:CVAC) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.
Profitability
This table compares CureVac and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
CureVac | N/A | N/A | N/A |
Regeneron Pharmaceuticals | 38.28% | 28.97% | 20.11% |
Earnings and Valuation
This table compares CureVac and Regeneron Pharmaceuticals' top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
CureVac | N/A | N/A | N/A | N/A | N/A |
Regeneron Pharmaceuticals | $7.86 billion | 6.87 | $2.12 billion | $21.47 | 23.49 |
Regeneron Pharmaceuticals has higher revenue and earnings than CureVac.
Insider and Institutional Ownership
4.3% of CureVac shares are owned by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and target prices for CureVac and Regeneron Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
CureVac | 1 | 1 | 2 | 0 | 2.25 |
Regeneron Pharmaceuticals | 0 | 5 | 14 | 1 | 2.80 |
CureVac presently has a consensus target price of $58.3333, suggesting a potential downside of 47.34%. Regeneron Pharmaceuticals has a consensus target price of $644.1739, suggesting a potential upside of 27.71%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than CureVac.
Summary
Regeneron Pharmaceuticals beats CureVac on 10 of the 10 factors compared between the two stocks.